cme.medlearning.de - CME Logo

Referenzen

  1. Bruckenberger E. Herzbericht 2004. In: http://www.bruckenberger.de/pdf/hzb17_04auszug.pdf
  2. Bruckenberger E. Herzbericht 2005. In:http://www.bruckenberger.de/pdf/hzb18_05auszug.pdf
  3. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804-847.
  4. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95:2037-2043.
  5. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med 2003; 138:777-786.
  6. McKay RG. "Ischemia-guided" versus "early invasive" strategies in the management of acute coronary syndrome/non-ST-segment elevation myocardial infarction: the interventionalist's perspective. J Am Coll Cardiol 2003; 41:96S-102S.
  7. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101:2557-2567.
  8. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.
  9. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-966.
  10. Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44:340-348.
  11. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J 1999; 20:1030-1038.
  12. Bundesärztekammer, AWMF, KBV. Nationale VersorgungsLeitlinie KHK 2006. In: http://www.versorgungsleitlinien.de/themen/khk.
  13. Assali AR, Moustapha A, Sdringola S, et al. Acute coronary syndrome may occur with in-stent restenosis and is associated with adverse outcomes (the PRESTO trial). Am J Cardiol 2006; 98:729-733.
  14. Schuhlen H, Kastrati A, Mehilli J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004; 147:317-322.
  15. Serruys PW, Ong ATL, Morice MC, et al. Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatement of patients with multivessel de novo coronary artery lesions. EuroInterv. 2005; 1:147 - 156.
  16. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002; 360:965-970.
  17. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
  18. Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993; 22:707-713.
  19. McGuire DK, Emanuelsson H, Granger CB, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000; 21:1750-1758.
  20. TAXUS TM Liberté , PackungsbeilageTM 90260871-01A, CE 0197, 2007.
  21. Cypher Select +, Packungsbeilage, 10578986.1,CE 0086, 2006.
  22. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-231.
  23. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46:575-581.
  24. Stone GW. DES Evidence-Based Medicine - Perspectives on Emerging Safety Concerns, Real World Outcomes and Use Recommendations. TCT 2006.
    www.tctmd.com.
  25. NICE. Ischaemic heart disease - coronary artery stents: Guidance. In:http://guidance.nice.org.uk/TA71/guidance/pdf/English: National Institute for Health and Clinical Excellence, 2003.
  26. Smith SC. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. In: http://www.acc.org/qualityandscience/clinical/guidelines/percutaneous/update/index.pdf.
  27. Dawkins KD, Grube E, Guagliumi G, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112:3306-3313.
  28. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
  29. Bernardi V, Szarfer J, Summay G, et al. Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007; 99:349-352.
  30. Grines CL, Bonow RO, Casey DE, Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734-739.
  31. Silber S. Cypher versus taxus: are there differences? J Interv Cardiol 2005; 18:441-446.
  32. Stone GW, Ellis SG, Cannon L et al. Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With a Bare Metal Stent in Patients With Complex Coronary Artery Disease. Jama 2005; 294: 1215-1223.
  33. Fajadet J, Wijns W, Laarman GJ. Randomized Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions. Circulation 2006; 114: 798-806.
  34. Silber S. Major Differences between the ESC and the ACC/AHA Guidelines for PCI. In: Transcatheter Cardiovascular Therapeutics. Washington, USA, www.crtonline.org, 2006.
  35. Holmes DR, Jr., Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. Jama 2006; 295:1264-1273.
  36. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. Jama 2006; 295:1253-1263.
  37. Mukherjee D, Moliterno DJ. Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. Jama 2006; 295:1307-1309.
  38. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355:1093-1104.
  39. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355:1105-1113.
  40. Van de Werf F. Drug-eluting stents in acute myocardial infarction. N Engl J Med 2006; 355:1169-1170.
  41. Biondi-Zoccai GG, Agostoni P, Abbate A, et al. Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 2005; 100:119-123.
  42. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. Jama 2005; 294:819-825.
  43. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 2006; 92:650-657.
  44. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. Jama 2006; 295:895-904.
  45. Galloe AM. SORT OUT II - A. Prospective, Multi-Center, Large-Scale, Randomized Trial of Paclitaxel- and Sirolimus-eluting Stents in "Real-World” Lesions: Nine-Month Clinical Results. In: Transcatheter Cardiovascular Therapeutics. Washington, USA, www.tct2006.com, 2006.
  46. Morice MC, Serruys PW. Poster: Prospective Randomized Multi-Center Head to Head Comparison of the Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-Eluting Stent (Taxus). In: ESC Kongress. Barcelona, Spanien, www.crtonline.org, 2006.
  47. Dörr R, Stumpf J, Spitzer SG. Sonderdruck. Aktuelle Daten aus Studien und Registern: Drug-eluting Stents für Diabetiker? ProPraxis Kardiologie 2006; Mai:27-29.
  48. Wöhrle J. Sind Drug-eluting Stents sicher und wirksam ? ProPraxis Kardiologie 2006; November/Dezember:30-33.
  49. Buchbinder M, Schampert E, Morice MC, Moses JW, Leon MB. Clinical and angiographic outcomes in diabetic patients: Integrated analysis of 6 Sirolimus-eluting versus bare metal-stent (BMS) trials. In: www.tct2006.com, ed., 2006.
  50. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989-997.
  51. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030-1039.
  52. Spaulding C, Daemen MD. Four-Year Follow-up of Sirolimus-eluting Stents in Comparison with Bare Metal Stents: A Pooled Safety Analysis of the RAVEL, SIRIUS, E-SIRIUS and C-SIRIUS Trial in 1748 Patients. FDA Panel 2006. In: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=672.
  53. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003; 108:43-47.
  54. Uren NG, Schwarzacher SP, Metz JA, et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J 2002; 23:124-132.
  55. Daemen J, Ong AT, Stefanini GG, et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 2006; 98:895-901.
  56. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. Jama 2005; 293:2126-2130.
  57. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051-1058.
  58. Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 2002; 55:142-147.
  59. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115:1433-1439; discussion 1439.
  60. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364:1519-1521.
  61. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol 2005; 45:941-946.
  62. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005; 45:954-959.
  63. Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947-953.
  64. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006; 98:352-356.
  65. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998-1008.
  66. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020-1029.
  67. Serruys P. FDA panel, 7 and 8 December 2006 - The impact on our practice and research. EuroInterv, 2007; 2: 405-407
  68. Baim D. FDA Panel on Drug-eluting Stent Safety December 7 and 8th 2006. Boston Scientific Presentation: Part I. In: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=672.
  69. Park DW, Park SW, Lee SW, et al. Frequency of Coronary Arterial Late Angiographic Stent Thrombosis (LAST) in the First Six Months: Outcomes With Drug-Eluting Stents Versus Bare Metal Stents. Am J Cardiol 2007; 99:774-778.
  70. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006; 113:1108-1113.
  71. Kahn J. TCT Daily: ESTROFA: late thrombosis not increased in DES patients: Spanish registry of drug-eluting stents shows STEMI, LAD artery lesions, significant risk factors. J Interv Cardiol 2007; 20:32.
  72. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369:667-678.
  73. Mishkel G, . Prairie "Real World" Drug Eluting Stent Database. FDA Circulatory System Devices Advisory Panel December 7-8, 2006. In: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=672.
  74. Chieffo A. TCT 2006. Influence of Prolonged Dual Anti-Platelet Use on Late Stent Thrombosis in a Large Real-World Registry: The Milan/Siegburg/Naples Experience. http://www.tctmd.com.
  75. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48:2584-2591.
  76. Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28:719-725.
  77. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115:1440-1455; discussion 1455.
  78. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006; 27:2784-2814.
  79. Baim D. FDA Panel on Drug-eluting Stent Safety December 7 and 8th 2006. Boston Scientific Presentation: Part II. In:
    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=672.
  80. Kaiser C, Brunner-La Rocca HP, Buser PT et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-
    metal stent in a real world setting: randomized Basel Stent Kosten Effectivitäts Trial (BASKET). Lancet 2005; 366: 921-929.
  81. Camenzind E, Steg G, Wijns W. Stent Thrombosis Late After Implantation of
    first-Generation Drug-Eluting Stents. Circulation 2007; 115: 1440-1455.
  82. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials
    comparing drug-eluting vs. bare metal stents in coronary artery disease: a
    meta-analysis. Eur Heart J 2007; 27: 2784-2814.
  83. Lagerqvist B, James SK, Stennestrand U et al. Long-Term Outcomes with
    Drug-Eluting Stents versus Bare-Metal Stents ind Sweden. N Engl J Med
    2007; 356: 1009-1019.
  84. Lagerqvist B, Wallentin L. FDA Panel on Drug-eluting Stent Safety
    December 7 and 8th. Long-term outcome of DES vs BMS implanted in
    Sweden 2003 - 2004, In:
    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg =672.
  85. Cubbon RM, Wheatcroft SB, Grant PJ et al. Temporal trends in mortality of
    patients with diabetes mellitus suffering acute myocardial infarction: a
    comparison of over 3000 patients between 1995 and 2003. Eur Heart J
    2007; 28: 540-545.
  86. Lenzen M, Ryden L et al. Diabetes known or newly detected, but not
    impaired glucose regulation, has a negative influence on 1-year outcome in
    patients with coronary artery disease: a report from the Euro Heart Survey
    on diabetes and the heart. Eur Heart J 2006; 27: 2969-2974.
  87. Maeng M. Stent Thrombosis after Implantation of Drug Eluting and Bare Metal
    Coronary Stents in Western Denmark. New Orleans, ACC 2007. In:
    http://www.cardiosource.com/annualmtg/acc07/Lectures.asp?sessiontitle=Late
    -Breaking%20Clinical%20Trials%20I&SessionID=14&date=3/24/2007
    .
  88. Rogers C et al. FDA Panel on Drug-eluting Stent Safety December 7 and 8th.
    Drug-Eluting Stent Safety Profile Stent Thrombosis.
    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg =672.
  89. Cohen SA. FDA Panel on Drug-eluting Stent Safety December 7 and 8th.
    "Real-World" Use of the CypherTM Sirolimus-Eluting Stent.
    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg =672.
  90. Update to FDA Statement on Coronary Drug-Eluting Stents
    http://www.fda.gov/cdrh/news/010407.html.
  91. Silber S, Böhm M, Gottwick M, Borggrefe M, Dietz R. Akutes Herzinfarktrisiko
    bei mangelnder Clopidogrelgabe nach koronarer Stentimplantation. Deutsches Ärzteblatt 2006; 103: A 2863 - A 2868
  92. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation. JAMA 2007; 297: 159-168.
  93. Wöhrle J. TCT 2006: Drug-eluting Stent Studienergebnisse. ProPraxis Kardiologie 2006; November/Dezember:34-36.
  94. Dawkins KD, Stone GW, Colombo A. Integrated analysis of medically treated diabetic patients in the TAXUS program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. EuroInterv.2006; 2:61-68.
  95. Leon MB. An Evidence-Based Medicine Appraisal of Clinical Indications for Drug-Eluting Stents - Appropriate Use, Abuse and Uncertainties. TCT 2006.
    www.tctmd.com.
  96. Windecker S, Remondino A., Eberli FR et al. Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularisation. N Engl J Med 2005; 353: 653-662
  97. Buch AN, Waksman R. Cypher Versus Taxus: All Smoke and No Fire: Lessons for Future Comparative Drug-Eluting Stent Trials in Interventional Cardiology. Am J Cardiol 2007; 99: 424-227
  98. Kappetein AP, Dawkins KD, Mohr FW et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. European Journal of Cardio-thoracic Surgery 2006; 29: 486-491
  99. Ong ATL, Serruys PW, Mohr FW et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. Am Heart J 2006; 151: 1194-1204
  100. Holmes Jr DR, Moses JW, Schofer J, Morice M-C, Schampaert E, Leon MB. Cause of death with bare metal and sirolimus-eluting stents. Eur Heart J 2006, 27: 2815 - 2822
  101.